Skip to main content
Evidence Snapshot

Cytochrome P450 2B6

CHEMBL4729 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4729
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cytochrome P450 2B6 as ChEMBL target CHEMBL4729, mapped to UniProt P20813. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cytochrome P450 2B6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4729
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P20813
Cytochrome P450 2B6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cytochrome P450 2B6 matters

As of 2026-09-13

Cytochrome P450 2B6 is reviewed as Cytochrome P450 2B6 (UniProt P20813); the current evidence base includes 16 approved drugs, 972 compounds, and 623 assays, with lead potency reaching pChEMBL 7.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 972 compounds, and 623 assays for this target. The dominant activity type is IC50. CHEMBL4175869 is the current potency anchor at pChEMBL 7.2.

Use CHEMBL4175869 as the tractability anchor when discussing potency (pChEMBL 7.2).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 7.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cytochrome P450 2B6 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P20813, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

972
Total Compounds
623
Total Assays
16
Approved Drugs
IC50: 638.0, KI: 54.0, EC50: 10.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4175869
 7.2 IC50 —
No preferred name
CHEMBL4160749
 7.2 IC50 —
No preferred name
CHEMBL4168669
 7.1 IC50 —
No preferred name
CHEMBL4165249
 7.1 IC50 —
No preferred name
CHEMBL4161819
 7.0 IC50 —

Approved Drugs

Structure Compound First Approval
CANNABIDIOL
CHEMBL190461
 2018
VORICONAZOLE
CHEMBL638
 2002
CLOPIDOGREL
CHEMBL1771
 1997
TICLOPIDINE
CHEMBL833
 1991
ETHINYL ESTRADIOL
CHEMBL691
 1982
TAMOXIFEN
CHEMBL83
 1977
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4729